Clinical Study of Umbilical Cord Tissue Mesenchymal Stem Cells (UC-MSC) for Treatment of Osteoarthritis

Translational Biosciences

Overview

Allogeneic human umbilical cord tissue-derived stem cells injected intravenously (IV) once per day for 3 days or once intra-articularly are a safe and will induce a therapeutic effect in osteoarthritis (OA) patients.

The proposed study will assess primarily safety and secondary efficacy endpoints of allogeneic umbilical cord mesenchymal stem cells (UC-MSC) administered to 40 patients with OA. Arm 1 will receive one intra-articular injection of UC-MSC into the knee and Arm 2 will receive IV UC-MSC once per day for 3 consecutive days. The primary objective of the trial is freedom from treatment associated adverse events at 3 and 12 months post treatment. Secondary objective will be efficacy as assessed at baseline, and 3 and 12 months post treatment and will be quantified based on the Western Ontario and McMaster osteoarthritis index (WOMAC).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Conditions

Osteoarthritis of the Knee

Interventions

Human umbilical cord tissue-derived mesenchymal stem cellsBIOLOGICAL

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Signed informed consent by the subject. * Age greater than or equal to 18 years * Ability to understand the planned treatment. * Idiopathic or secondary osteoarthritis of the knee with grade 2, 3, or 4 radiographic severity, as defined by the modified Kellgren-Lawrence classification Exclusion Criteria: * Pregnant or lactating women * Women of childbearing potential unwilling to use two forms of contraception * Cognitively impaired adults. * Presence of large meniscal tears ("bucket handle" tears), as detected by clinical examination or by magnetic resonance imaging. * Inflammatory or postinfectious arthritis. * More than 5 degrees of varus or valgus deformity. * Kellgren Lawrence grade 4 osteoarthritis in two compartments (the medial or lateral compartments of the tibiofemoral joint or the patellofemoral compartment) in persons over 60 years of age. * Intraarticular corticosteroid injection within the previous 3 months. * A major neurologic deficit. * Serious medical illness with a life expectancy of less than 1 year. * Prior admission for substance abuse * Body Mass Index (BMI) of 40 kg/m2 or greater * Patient receiving experimental medication or participating in another clinical study within 30 days of signing the informed consent * In the opinion of the investigator or the sponsor the patient is unsuitable for cellular therapy

Locations (1)

Stem Cell Instsitute

Panama City, Panama

Outcomes

Primary Outcomes

Number of participants with adverse events

Time frame: 3 months and 12 months

Secondary Outcomes

Number of participants with a change in joint function from baseline WOMAC assessment

Time frame: 3 months and 12 months

Number of participants with a change in radiogrpahic evidence of knee OA from baseline Kellegren-Lawrence grading system

Time frame: 3 months and 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.